Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This international study collects real-world data on adults born with heart defects who have started taking SGLT2 inhibitor medicines (SGLT2i). It looks at how these medicines are prescribed, their safety and side effects, and whether they may help with heart failure, when the heart does not pump blood well enough.
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- You were born with a heart defect.
- You are 18 or older.
- You have started treatment with an SGLT2 inhibitor medicine.
Who can't join
- You do not agree to have your data collected.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Congenital heart defect. * Age ≥ 18 years. * Initiated on treatment with an SGLT2i. Exclusion Criteria: \- No consent for data collection.
Study sites (3)
MD
- Johns Hopkins University · Baltimore, MD 21205Ari M. Cedars, MD PhD · Principal investigatorMore trials in Baltimore
MI
- Helen DeVos Children's Hospital · Grand Rapids, MI 49503Gruschen R. Veldtman, MBChB FRCP · Principal investigatorMore trials in Grand Rapids
NY
- Mount Sinai Fuster Heart Hospital · New York, NY 10029Ali Zaidi, MD · Principal investigatorMore trials in New York